Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneDx HoldingsWGS +5.46%66 Cash-to-Debt is 0.79 as of Jun. 2026, which is 48% below its 10-year median of 1.51. GuruFocus rates WGS with a GF Score™ of 66/100 and a GF Value™ of $74.11 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, GeneDx Holdings ranks worse than 56.25% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. GeneDx Holdings's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.79.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, GeneDx Holdingscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for GeneDx Holdings's Cash-to-Debt or its related term are showing as below:
WGS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.79 Med: 1.51 Max: 41.93
Current: 0.79
During the past 6 years, GeneDx Holdings's highest Cash to Debt Ratio was 41.93. The lowest was 0.79. And the median was 1.51.
WGS's Cash-to-Debt is ranked worse than 56.25% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.98
vs WGS: 0.79
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
GeneDx Holdings Cash-to-Debt Related Terms
GeneDx Holdings Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for GeneDx Holdings's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Diagnostics & Research subindustry, GeneDx Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneDx Holdings Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where GeneDx Holdings's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneDx Holdings (WGS) has a Cash-to-Debt of 0.79 as of Jun. 2026. This is 48% below median its historical median of 1.51. Over the past decade, GeneDx Holdings' Cash-to-Debt has ranged from 0.79 to 41.93. According to the industry distribution chart, GeneDx Holdings ranks #117 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 56.2%.
Is GeneDx Holdings' Cash-to-Debt too high?
GeneDx Holdings' current Cash-to-Debt of 0.79 is 48% below median its 10-year median of 1.51. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 41.93. The Medical Diagnostics & Research industry median Cash-to-Debt is 0.98. GeneDx Holdings' value of 0.79 is 19.4% below this industry median. Based on the distribution chart, GeneDx Holdings ranks #117 out of 208 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, GeneDx Holdings has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Cash-to-Debt compare to CDNA and NEO?
According to the Medical Diagnostics & Research industry distribution chart, GeneDx Holdings ranks #117 out of 208 companies for Cash-to-Debt. This places GeneDx Holdings in the lower half of its industry. The industry median Cash-to-Debt is 0.98. GeneDx Holdings' value of 0.79 is 19.4% below this benchmark. Historically, GeneDx Holdings' own Cash-to-Debt has ranged from 0.79 to 41.93 over the past decade. While the company's 10-year median is 1.51 vs. the industry median of 0.98, GeneDx Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 0.98, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneDx Holdings's current Cash-to-Debt of 0.79 is 19.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneDx Holdings's current Cash-to-Debt is 0.79, which is 48% below median its own 10-year median of 1.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $74.11, compared to a current price of $94.64 — trading 27.7% above its estimated fair value. The current Cash-to-Debt is 0.79, which is 48% below median its 10-year median of 1.51 and 19.4% below the Medical Diagnostics & Research industry median of 0.98. GeneDx Holdings' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Cash-to-Debt is 0.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneDx Holdings (WGS) Overvalued in 2026?
Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued.
The current stock price of $94.64 is trading 27.7% above its estimated GF Value™ of $74.11.
GuruFocus considers GeneDx Holdings to be Modestly Overvalued.
Key valuation signals for WGS:
Cash-to-Debt: 0.79 (48% below median its 10-year median of 1.51)
GF Value™: $74.11 vs. price of $94.64 (27.7% above fair value)
Industry Position: 19.4% below the Medical Diagnostics & Research median (#117 of 208)
No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
66GF Score
Get the complete analysis for WGS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WGS has been successfully added to your 
